Ling Han

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

Rohit Loomba, Eric Lawitz, Parvez Mantry et al. · Hepatology · 2017 · 541 citations · Full text

Collagen Content, Pathology, Cell Death +17

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Quentin M. Anstee, Eric Lawitz, Naim Alkhouri et al. · Hepatology · 2019 · 258 citations

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

Eric Lawitz, Angie Coste, Fred Poordad et al. · Clinical Gastroenterology and Hepatology · 2018 · 213 citations

Metabolic Syndrome, Metabolic Associated Steatohepatitis, Hepatology +12

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

Saumya Jayakumar, Michael S. Middleton, Eric Lawitz et al. · Journal of Hepatology · 2018 · 196 citations

A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH

Amaro Taylor‐Weiner, Harsha Pokkalla, Ling Han et al. · Hepatology · 2021 · 189 citations · Full text